INACTIVE/DISSOLVED
Founded
2003
Website
Business classification
VCID: 345040
Profile
Corporate information
Official name
Santaris Pharma A/S
Registration country
Official name
Santaris Pharma A/S
Registration country
Investment activity status
Active investor
Overview
Santaris Pharma A/S uses its proprietary Locked Nucleic Acid (LNA) platform and tissue-targeting expertise to pioneer next-generation antisense product candidates. Santaris Pharma is developing a diverse pipeline of LNA therapeutics that influence the production or activity of select RNA targets to address diseases that are difficult-to-treat with conventional drug modalities. Santaris Pharma’s innovation and leadership position has attracted multiple collaborations with leading global pharmaceutical companies. Founded in 2003, Santaris Pharma is headquartered in Denmark.
Funding
Funding rounds
Acquisition USD 450,000,000
USD 450,000,000 (4 Aug 2014) at USD 450,000,000 valuation. Change in valuation: unknown
USD 250 million valuation plus up to USD 200 million in milestone payments.
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
Roche Holding AG | USD 450,000,000 (USD 450,000,000). Initial investment. Led the round. |
(1 Jun 2012) Change in valuation: unknown
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
Forbion Capital Partners Management Services BV | Netherlands | USD Initial investment. Round participant. | |
|
Gilde Healthcare Partners BV | Netherlands | Initial investment. Round participant. | |
|
|
Global Life Science Ventures GmbH | Germany | Initial investment. Round participant. | |
|
Novo A/S | Denmark | Initial investment. Round participant. | |
|
Seventure Partners SA | Venture capital firm with a focus on hight growth European companies in the areas of information and communications technologies and life sciences | France | Initial investment. Round participant. |
Cap Table
Current and past shareholders
| Investor | Contacts | Round | |
|---|---|---|---|
|
|
Forbion Capital Partners Management Services BV |
+31 (35) 699-3000 |
Venture |
|
|
Gilde Healthcare Partners BV |
+31 (30) 219-2536 |
Venture |
|
|
Global Life Science Ventures GmbH |
+49 (89) 288-1510 |
Venture |
|
|
Novo A/S |
Venture | |
|
|
Roche Holding AG |
Acquisition | |
|
|
Seventure Partners SA Venture capital firm with a focus on hight growth European companies in the areas of information and communications technologies and life sciences |
+33 (1) 5819-2270 |
Venture |
|
Sunstone Life Science Ventures |
N/A |